Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Buy” by Analysts

Xencor, Inc. (NASDAQ:XNCR) has earned an average recommendation of “Buy” from the nine analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $34.78.

Several research analysts have commented on XNCR shares. Wedbush restated an “outperform” rating and issued a $34.00 target price on shares of Xencor in a research note on Monday, September 9th. BMO Capital Markets reiterated an “outperform” rating and issued a $32.00 target price on shares of Xencor in a research note on Tuesday, August 6th. JPMorgan Chase & Co. reduced their price target on shares of Xencor from $30.00 to $27.00 and set an “overweight” rating for the company in a research report on Wednesday, July 31st. Finally, Royal Bank of Canada lifted their price objective on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday, September 26th.

Xencor Stock Up 1.2 %

XNCR stock opened at $21.26 on Friday. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -7.36 and a beta of 0.66. Xencor has a fifty-two week low of $15.31 and a fifty-two week high of $26.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.92 and a current ratio of 6.92. The stock has a fifty day moving average of $19.93 and a 200-day moving average of $20.13.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.25). Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The business had revenue of $16.96 million for the quarter, compared to analysts’ expectations of $21.13 million. During the same quarter in the previous year, the company posted ($0.37) earnings per share. The business’s quarterly revenue was down 62.7% compared to the same quarter last year. As a group, equities research analysts predict that Xencor will post -4.11 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in XNCR. Diversified Trust Co grew its holdings in shares of Xencor by 4.5% during the 1st quarter. Diversified Trust Co now owns 13,059 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 563 shares during the last quarter. Texas Permanent School Fund Corp lifted its stake in shares of Xencor by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 53,277 shares of the biopharmaceutical company’s stock valued at $1,179,000 after acquiring an additional 690 shares during the last quarter. Linden Thomas Advisory Services LLC lifted its stake in shares of Xencor by 1.6% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company’s stock valued at $826,000 after acquiring an additional 699 shares during the last quarter. Baillie Gifford & Co. boosted its holdings in Xencor by 3.3% during the 2nd quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company’s stock valued at $445,000 after acquiring an additional 744 shares during the period. Finally, Louisiana State Employees Retirement System grew its position in Xencor by 3.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock worth $587,000 after acquiring an additional 900 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.